News

Under the deal, the companies will establish a learning facility – ‘McLaren GSK Centre for Applied Performance’ – to develop UK engineering skills and processes. Employees from both

NanoViricides anticipates that it will be using the space in the near future for laboratory facilities and cGMP production of its nanoviricides drug candidates against various viral diseases.

GE Healthcare vice president and CTO Mike Harsh said the only way they can facilitate clinicians to eradicate cancer is to provide them the tools to find it

The latest generation technology used by Mevopur additives reduces cycle times by improving rate of crystallization and the crystallization temperature versus conventional technology in homopolymer and random copolymer

Pall’s net earnings were $97.35m for the fourth quarter ended 31 July 2011, compared to $54.96m for the same period in 2010. For the full year ended 31

Currently under development by Viamet Pharma,VT-1161 is intended for the treatment of fungal infections in humans. Viamet president and CEO Robert Schotzinger said in preclinical studies, VT-1161 has

KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), is in Phase 2 clinical

As per the agreement held during 2009, Pennsaid Viscous Solution is being handled by Nuvo’s licensee – Covidien and it has assumed all responsibility for managing, executing and

The agreement allows ChemPartner to conduct pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and